GeneDx Holdings Corp. (WGS) stock
WGSNasdaqServices-Health ServicesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/3043% above fair value
$45.46−3.78 (-7.68%)
Close on Nov 20, 2026Market cap $1.36BP/E –Yield –
GeneDx free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
GeneDx's free cash flow for the twelve months ending Jun 30, 2026 was -$75.80M, down 9232.3% year over year. For fiscal 2025 it was $14.26M. The highest annual figure on record is $14.26M in fiscal 2025.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.26M | – |
| FY2024 | Dec 31, 2024 | -$33.99M | – |
| FY2023 | Dec 31, 2023 | -$185.40M | – |
| FY2022 | Dec 31, 2022 | -$326.31M | – |
| FY2021 | Dec 31, 2021 | -$199.83M | – |
| FY2020 | Dec 31, 2020 | -$117.22M | – |
| FY2019 | Dec 31, 2019 | -$30.65M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$39.10M | -585.6% |
| Q1 FY2026 | Mar 31, 2026 | -$38.86M | -1058.8% |
| Q4 FY2025 | Dec 31, 2025 | -$7.44M | – |
| Q3 FY2025 | Sep 30, 2025 | $9.60M | – |
| Q2 FY2025 | Jun 30, 2025 | $8.05M | – |
| Q1 FY2025 | Mar 31, 2025 | $4.05M | – |
| Q4 FY2024 | Dec 31, 2024 | -$6.23M | – |
| Q3 FY2024 | Sep 30, 2024 | -$5.04M | – |
| Q2 FY2024 | Jun 30, 2024 | -$5.86M | – |
| Q1 FY2024 | Mar 31, 2024 | -$16.86M | – |
| Q4 FY2023 | Dec 31, 2023 | -$32.23M | – |
| Q3 FY2023 | Sep 30, 2023 | -$41.34M | – |
| Q2 FY2023 | Jun 30, 2023 | -$56.26M | – |
| Q1 FY2023 | Mar 31, 2023 | -$55.56M | – |
| Q4 FY2022 | Dec 31, 2022 | -$66.82M | – |
| Q3 FY2022 | Sep 30, 2022 | -$90.60M | – |
| Q2 FY2022 | Jun 30, 2022 | -$86.02M | – |
| Q1 FY2022 | Mar 31, 2022 | -$82.87M | – |
| Q4 FY2021 | Dec 31, 2021 | -$57.04M | – |
| Q3 FY2021 | Sep 30, 2021 | -$71.96M | – |
| Q2 FY2021 | Jun 30, 2021 | -$26.55M | – |
| Q1 FY2021 | Mar 31, 2021 | -$44.28M | – |
| Q4 FY2020 | Dec 31, 2020 | -$25.12M | – |
See a number that looks wrong?